Replies to post #46392 on RespireRx Pharmaceuticals Inc (RSPI)

[waterpro42]

Great point!

[INV4]

RespireRx noted that Clodfelter has extensive experience providing business development, strategy, and valuation consulting services to pharmaceutical, biotech and medical device companies, where he has led or been a core member on over 30 international and domestic pharmaceutical licensing and device negotiations ranging from preclinical to launched products.

He previously held positions at Eli Lilly CO (NYSE: LLY) and Amylin Pharmaceuticals, as well as California-based biotechnology firms Medicus Biosciences and Advance Therapeutics.

"I believe that RespireRx has novel and unique drug development programs that address large markets with considerable unmet needs, Clodfelter commented.

"I look forward to contributing to the realization of their value."

==============

RespireRX Pharmaceuticals makes key part time hire to drive business

Published: 11 Dec 2023

RespireRx Pharmaceuticals (OTC:RSPI) has announced an agreement with Ponto Ventures LLC under which Will Clodfelter will serve as its senior vice president of business development on a part-time basis.

Clodfelter is the founder and managing director of Ponto Ventures, a biotech and device strategy consulting firm.

He will initially lead the business development efforts for dronabinol, the lead asset of the company’s Australian subsidiary, ResolutionRx Ltd, in collaboration with senior vice president, chief financial officer, treasury and secretary, Jeff Margolis.

“His involvement adds considerable depth and experience to our financial and business activities being conducted to set up our programs for investment, partnering or sale,” Margolis said in a statement.

“While his initial efforts will focus on the ResolutionRx dronabinol program, I am certain that his efforts will also extend to our other programs.”

RespireRx noted that Clodfelter has extensive experience providing business development, strategy, and valuation consulting services to pharmaceutical, biotech and medical device companies, where he has led or been a core member on over 30 international and domestic pharmaceutical licensing and device negotiations ranging from preclinical to launched products.

He previously held positions at Eli Lilly and Co (NYSE:LLY) and Amylin Pharmaceuticals, as well as California-based biotechnology firms Medicus Biosciences and Abvance Therapeutics.

“I believe that RespireRx has novel and unique drug development programs that address large markets with considerable unmet needs,” Clodfelter commented.

“I look forward to contributing to the realization of their value.”

RespireRx Pharmaceuticals (OTC:RSPI) and its subsidiaries and business units (RespireRx Group) are discovering and developing medicines for the treatment of psychiatric and neurological disorders, including obstructive sleep apnea (OSA), attention deficit hyperactivity disorder (ADHD), epilepsy, pain, recovery from spinal cord injury (SCI), and certain neurological orphan diseases.

https://www.proactiveinvestors.com/companies/news/1048863/rakovina-therapeutics-kicks-off-2024-with-strategic-pivot-to-ai-drug-development-1048863.html

$RSPI

[LTListener]

Exactly. That hire brought in a skillset to structure company and set up their various programs for partnering or funding.

Initial PR mentioned getting additional funding for OSA program, but judging by preclinical results and publications about KRM-ll-81 potential impact on epilepsy AND pain management, one can envision multiple partnerships possibly in the works for moving that drug into various human trials as well, which is strongly suggested by the entire body of their preclinical efforts..

Traders will now add liquidity and unfortunately tons of volatility, but underlying all of this is a strong pipeline of candidate drugs with very positive preclinical results to address severe unmet pharmaceutical needs for patients with OSA, epilepsy and pain.

Given the ridiculous market valuation of less than 3 million, one can speculate what is plausible considering other otc pharma companies that had merely a fraction of the potential with less preclinical efforts confirming such potential!

[powerbattles]

Great DD thanks.